Towards a new spatial representation of bone remodeling by Jason M. Graham, Bruce P. Ayati, Prem S. Ramakrishnan, James A. Martin

“…Irregular bone remodeling is associated with a number of bone diseases such as osteoporosis and multiple myeloma. Computational and mathematical modeling can aid in therapy and treatment as well as understanding fundamental biology. …”
Get full text

Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes by Yan-Hua Wang, Shotaro Hagiwara, Hiroshi Kazama, Yuki Iizuka, Norina Tanaka, Junji Tanaka

“…Multiple myeloma (MM) is an intractable hematological malignancy caused by abnormalities in plasma cells. …”
Get full text

Successful Treatment of Plasma Cell-Rich Acute Rejection Using Bortezomib: A Case Report by Sara Hashemi, Reut Hod-Dvorai, Rebecca Tong, Liye Suo

“…Bortezomib is a proteasome inhibitor that prevents cell proliferation by inducing apoptosis in plasma cells and has shown great promise as a therapeutic agent for multiple myeloma. Our case suggests that bortezomib can also be used as a potential therapeutic intervention for patients with PCAR.…”
Get full text

Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3 by Marc Beyer, Sabine Classen, Elmar Endl, Matthias Kochanek, Martin R. Weihrauch, Svenja Debey-Pascher, Percy A. Knolle, Joachim L. Schultze

“…We have reported an expanded pool of CD4+CD25high Treg cells in patients with chronic lymphatic leukemia (CLL), multiple myeloma (MM) as well as its premalignant precursor monoclonal gammopathy of undetermined significance (MGUS). …”
Get full text

Deep Venous Thrombosis in Patients with Erythema Nodosum Leprosum in the Use of Thalidomide and Systemic Corticosteroid in Reference Service in Belo Horizonte, Minas Gerais by Luiz Alberto Bomjardim Pôrto, Maria Aparecida de Faria Grossi, Edilamar Silva de Alecrim, Marcus Henrique de Souza Brito Xavier, Frederico Paiva e Silva, Amalia Sathler Pires, Fabianny Sanglard da Silva, Sandra Lyon

“…DVT increased in association with thalidomide/corticosteroid in multiple myeloma, but this complication is poorly described in ENL. …”
Get full text

Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group by Natasha Ali, Raheel Iftikhar, Muhammad Ayaz Mir, Syed Waqas Bokhari, Jehanzeb Ur Rehman, Uzma Zaidi, Shahzad Nasir, Salman Naseem Adil, Tariq Satti, Qamar Un Nisa Chaudhry, Muhammad Farhan, Tasneem Farzana, Tariq Ghafoor, Bushra Ahsan, Azhar S. Khan, Farrukh Ali Khan, Syeda Itrat Fatima, Shafaq Abdul Samad, Aliya Batool, Hafiz Muhammad Nadeem, Syed Nasir Abbas Bukhari, Saqib Hussain Ansari, Parvez Ahmed

“…Autologous transplants were more frequently performed for Hodgkin’s lymphoma as compared to non-Hodgkin’s lymphoma and multiple myeloma. The use of peripheral and bone marrow stem cells was comparable. …”
Get full text

Melanoma bone metastasis-induced osteocyte ferroptosis via the HIF1α-HMOX1 axis by Yewei Jia, Rui Li, Yixuan Li, Katerina Kachler, Xianyi Meng, Andreas Gießl, Yi Qin, Fulin Zhang, Ning Liu, Darja Andreev, Georg Schett, Aline Bozec

“…Elevated osteocyte apoptosis has been observed in lytic bone lesions of patients with multiple myeloma. However, their precise contribution to bone metastasis remains unclear. …”
Get full text

Monoclonal Gammopathy of Undetermined Significance with Amyloid Deposition in the Lung and Non-Amyloid Eosinophilic Deposition in the Brain: A Case Report by Francois Abi-Fadel, Nisarg R. Desai, Gita Vatandoust, Rabih Said, Aaron Gottesman, Terenig Terjanian

“…As MGUS might be complicated by diseases such as amyloidosis and multiple myeloma, a scheduled follow-up of these patients is always necessary. …”
Get full text

Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experience by Orla McCourt, Joanne Land, Neil Rabin, Kwee Yong, Abi Fisher, Jonathan Sive, Charalampia Kyriakou, Michael K Luong, Alasdair Longden

“…Functional (6 min walk and timed sit-to-stand tests) and patient-reported outcome measures (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-C30) and EuroQol EQ5D-5L were assessed at preharvest, preadmission and in the post-ASCT evaluation (day 100) clinic.Results Patients (n=46) with a diagnosis of multiple myeloma referred for ASCT following induction chemotherapy were assessed. …”
Get full text

Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis–Arbuzov or the Pudovik Reaction by Zsuzsanna Szalai, Janka Bednárik, Boldizsár Szigfrid Tóth, Angéla Takács, Szilárd Tekula, László Kőhidai, Konstantin Karaghiosoff, László Drahos, György Keglevich

“…A part of the derivatives revealed a significant cytotoxic effect on pancreatic adenocarcinoma or multiple myeloma cells. <b>Conclusions:</b> The new families of compounds synthesized by our novel approaches may be of practical importance due to the significant cytotoxic activity on the cell cultures investigated. …”
Get full text

Femoral Head Pathology in Subcapital Hip Fractures: Clinical Value and Cost-Effectiveness in a 230-Patient Case Series by Nissim Ohana, Omer Marom, David Segal, Refael Behrbalk, Yuval Ben-Sira, Alex Tavdi, Ezequiel Palmanovich, Eyal Yaacobi

“…The most common malignancies detected were breast cancer and multiple myeloma (three cases each). None of the findings led to changes in patient management. …”
Get full text

Preliminary Effectiveness of a Telehealth-Delivered Exercise Program in Older Adults Living With and Beyond Cancer: Retrospective Study by Emily R Dunston, Sonal Oza, Yang Bai, Maria Newton, Leslie Podlog, Kish Larson, Darren Walker, Rebecca W Zingg, Pamela A Hansen, Adriana M Coletta

“…The 3 most common cancer types in this sample were breast (n=13), prostate (n=13), and multiple myeloma (n=8). All cancer stages were represented in this sample with stage II (n=16, 23.5%) and III (n=18, 26.5%) being the most common. …”
Get full text

An NMR Study of the Bortezomib Degradation under Clinical Use Conditions by Adele Bolognese, Anna Esposito, Michele Manfra, Lucio Catalano, Fara Petruzziello, Maria Carmen Martorelli, Raffaella Pagliuca, Vittoria Mazzarelli, Maria Ottiero, Melania Scalfaro, Bruno Rotoli

“…The (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl-boronic acid, bortezomib (BTZ), which binds the 20S proteasome subunit and causes a large inhibition of its activity, is a peptidomimetic boronic drug mainly used for the treatment of multiple myeloma. Commercial BTZ, stabilized as mannitol derivative, has been investigated under the common conditions of the clinical use because it is suspected to be easily degradable in the region of its boronic moiety. …”
Get full text

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity by Jeremy Loyau, Thierry Monney, Marco Montefiori, Fedir Bokhovchuk, Jeremy Streuli, Matthew Blackburn, Arnaud Goepfert, Lydia N. Caro, Samitabh Chakraborti, Stefania De Angelis, Camille Grandclément, Stanislas Blein, M. Lamine Mbow, Ankita Srivastava, Mario Perro, Stefano Sammicheli, Eugene A. Zhukovsky, Michael Dyson, Cyrille Dreyfus

“…The superior CD38 targeting of ISB 1442, at both high and low receptor densities, by its biparatopic design, will enhance proximal CD47 blockade and thus counteract a major tumor escape mechanism in multiple myeloma patients.…”
Get full text

Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells by Anthony M. Battram, Joan Mañé-Pujol, David F. Moreno, Aina Oliver-Caldés, Judit Carpio, Oriol Cardus, Luis Gerardo Rodríguez-Lobato, Álvaro Urbano-Ispizua, Carlos Fernández de Larrea

“…Abstract: Chimeric antigen receptor (CAR) T cells directed against B-cell maturation antigen (BCMA) are an effective treatment for multiple myeloma (MM), but short persistence and frequent relapses are challenges for this immunotherapy. …”
Get full text

MicroRNAs as Haematopoiesis Regulators by Ram Babu Undi, Ravinder Kandi, Ravi Kumar Gutti

“…Aberrant expression of miRNAs was observed in hematological malignancies including chronic myelogenous leukemia, chronic lymphocytic leukemia, multiple myelomas, and B cell lymphomas. In this review we have focused on discussing the role of miRNA in haematopoiesis.…”
Get full text